Physician profile
William C Tidmore
NPI 1073695292
$3,030.54
in general payments reported to CMS, 2019-2025
26 companies · $781 in 2025
The $781 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $195 · 2021: $57.16 · 2022: $128 · 2023: $652 · 2024: $1,115 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,515 · Education: $32.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.19 |
| Education | $32.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.26 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $296.25 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $288.77 | 2020-2025 | Evenity, Tepezza, Repatha |
| Pfizer INC. | $283.22 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $270.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $181.00 | 2020-2025 | Benlysta |
| Genzyme Corporation | $166.39 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $109.24 | 2023-2025 | Lupkynis |
| Radius Health, INC. | $106.70 | 2019-2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $102.35 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $99.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.87 | 2020-2024 | Orencia |
| Ani Pharmaceuticals, INC. | $70.04 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $55.69 | 2019-2024 | Actemra |
| Dexcom, INC. | $50.15 | 2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $44.53 | 2024 | Acthar |
| Novo Nordisk INC | $39.10 | 2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $32.83 | 2020-2023 | Tepezza |
| Fresenius Kabi USA, LLC | $22.58 | 2025 | Tyenne |
| Averitas Pharma INC. | $20.70 | 2025 | Qutenza |
| Chiesi USA, INC. | $18.24 | 2025 | Myalept |
| Seqirus USA INC | $17.17 | 2025 | Fluad, Flucelvax |
| Ascensia Diabetes Care US INC. | $16.08 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.97 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $15.57 | 2025 | Yorvipath |
| Medtronic, INC. | $13.60 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tidmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.